Current Report Filing (8-k)
August 19 2022 - 08:31AM
Edgar (US Regulatory)
0001094038 false 0001094038 2022-08-16
2022-08-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
August 16, 2022
Date of Report (Date of earliest event reported)
MARKER THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-37939 |
45-4497941 |
(State or other
jurisdiction of incorporation) |
(Commission File
Number) |
(IRS Employer
Identification No.) |
3200 Southwest Freeway
Suite 2500
Houston,
Texas
|
|
77027 |
(Address of principal
executive offices) |
|
(Zip Code) |
(713) 400-6400
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of
each class |
|
Trading
Symbol(s) |
|
Name of each
exchange on which registered |
Common Stock, par value $0.001 per share |
|
MRKR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ¨
|
Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing. |
As previously reported, on February 16, 2022, Marker
Therapeutics, Inc. (the “Company”) received a
notice from The Nasdaq Stock Market (“Nasdaq”) that
the Company was not in compliance with Nasdaq’s Listing
Rule 5450(a)(1), as the minimum bid price of the Company’s
common stock had been below $1.00 per share for 30
consecutive business days. The Company was granted 180 calendar
days, or until August 15, 2022, to regain compliance with the
minimum bid price requirement. On August 16, 2022, Nasdaq
approved the Company’s application to transfer to The Nasdaq
Capital Market, effective at the opening of business on
August 18, 2022, and notified the Company that it had been
granted an additional 180-calendar day compliance period, or until
February 13, 2023, to regain compliance with the minimum bid
price requirement. As part of the transfer, the Company provided
notice to Nasdaq that it intended to cure the bid price deficiency
by effecting a reverse stock split, if necessary, prior to the end
of the compliance period. The Company’s failure to regain
compliance during this period could result in delisting, which the
Company could appeal to a Nasdaq hearings panel.
The Company intends to actively monitor the bid price of its common
stock and will consider available options, including a reverse
stock split, to regain compliance with the listing requirements.
There can be no assurance that the Company will be able to regain
compliance with Nasdaq’s Listing Rule 5450(a)(1) or will
otherwise be in compliance with other Nasdaq listing criteria.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
Marker
Therapeutics, Inc. |
|
|
|
Dated:
August 19, 2022 |
By: |
/s/
Peter Hoang |
|
|
Peter
Hoang |
|
|
President
and Chief Executive Officer |
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Dec 2022 to Jan 2023
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Jan 2022 to Jan 2023